Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Today tags : Therapeutics save search
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 07:00) - prnewswire.com
AKBA | $1.36 -0.73% -0.74% 1.5M
|
Health Technology
|
| O: 0.0%
H: 2.19%
C: 0.0%
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -3.21%
H: 0.0%
C: 0.0%
filspari nephropathy treatment for therapeutics
Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
Published: 2024-04-24 (Crawled : 07:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
precision company million series therapeutics
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
Published: 2024-04-24 (Crawled : 08:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
drug for therapeutics development
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -3.21%
H: 0.0%
C: 0.0%
filspari nephropathy treatment for therapeutics
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
CMMB | $0.67 0.02% 3.4K
|
Manufacturing
|
| O: 1.49%
H: 0.0%
C: -1.47%
first report business update therapeutics financial results
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
first therapeutics
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
CGEM | $18.9 13.38% 11.8% 1.2M
|
|
| O: 0.12%
H: 17.14%
C: 13.18%
cln-619 asco tumors therapeutics advanced study
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: 0.0%
H: 0.67%
C: -8.75%
bxcl701 keytruda presentation asco pancreatic for meeting trial therapeutics
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
HOWL | $6.405 -0.54% -0.55% 82K
|
Professional, Scientific, and T...
|
| O: -0.93%
H: 4.23%
C: 0.16%
wtx-124 presentation for meeting therapeutics
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Published: 2024-04-24 (Crawled : 13:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
first therapeutics financial results
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Published: 2024-04-24 (Crawled : 13:00) - biospace.com/
HRTX M | $2.66 -5.0% -5.26% 2.2M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
first report therapeutics financial results
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
KTTA | $7.09 -1.19% 910
|
| Email alert
Add to watchlist
pas-004 first trial therapeutics
Avenue Therapeutics Announces Reverse Stock Split
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
FBIO | $1.785 -1.38% -1.4% 120K
|
Health Technology
|
| O: -0.56%
H: 0.56%
C: 0.0%
ATXI | $0.0949 -29.18% -41.2% 12M
|
Health Technology
|
| O: -23.08%
H: 0.0%
C: -10.0%
therapeutics
Actym Therapeutics Appoints Thomas Smart as CEO
Published: 2024-04-24 (Crawled : 13:00) - prnewswire.com
ANAB | $19.25 0.37% 0.36% 390K
|
Health Technology
|
| O: -0.89%
H: 1.47%
C: 1.37%
ceo smart therapeutics
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CYTO | $1.495 -5.38% -5.69% 3M
|
Manufacturing
|
| O: 1.27%
H: 0.0%
C: -10.0%
positive publication bentrio trial therapeutics results
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: -0.29%
H: 0.0%
C: 0.0%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CAPR | $5.04 4.56% 4.37% 910K
|
Health Technology
|
| O: 9.13%
H: 7.41%
C: -4.18%
cap-1002 fda positive program therapeutics duchenne type-b meeting
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
first report corporation therapeutics financial results market
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
CDTX | News | $11.94 16.49% 14.15% 170K
|
Health Technology
| Email alert
Add to watchlist
cloudbreak rezafungin pipeline therapeutics development
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
ACRV | $9.46 -3.67% -3.81% 300K
|
| Email alert
Add to watchlist
acr-368 positive pipeline for program therapeutics today
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.